You will be shown inclusion or exclusion criteria for a clinical trial. Given these criteria, your task is to extract all unique entities of the following types: ["Observation", "Condition", "Procedure", "Drug", "Temporal", "Multiplier", "Qualifier", "Negation", "ReferencePoint", "Scope", "Value", "Mood", "Device", "Visit", "Measurement", "Person"].

Please return the output as a JSON object of the format: {"Condition" : ["breast cancer", ...], "Device" : ["ports", ...], "Drug" : ["Atenolol", ...], "Measurement" : ["blood pressure", ...], "Mood" : ["suspected", ...], "Multiplier" : ["more than two", ...], "Negation" : ["no", ...], "Observation" : ["history", ...], "Person" : ["male", ...], "Procedure" : ["surgery", ...], "Qualifier" : ["severe", ...], "ReferencePoint" : ["enrollment", ...], "Scope" : ["infection", ...], "Temporal" : ["one day", ...], "Value" : ["50%", ...], "Visit" : ["ICU", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

-Patients residing in the following clinical states wit! be considered: A. Rising PSA: Patients with a history of localized disease who have undergone definitive radiation or surgery. These patients must demonstrate progression of disease biochemically as outlined below. Patients in this group may not have radiographically evident disease. 
B. Non-castrate metastatic: Patients must present with radiographic evidence of metastatic disease at the time of diagnosis or after treatment for localized disease. These patients must show newly detected disease or progressing disease in bone or in soft tissue. Biochemical progression is defined as: minimum no. of determinations: 3 Interval: >2 weeks Minimal Baseline PSA value (ng/ml): 2 Minimal % increase in range of values: 50% 
Diagnosis of prostate adenocarcinoma histologically confirmed at MSKCC. 
Patient must have level of serum testosterone above the lower limit of normal. 
Karnofskcy performance status (KPS) >_70%. 
Patients must have adequate organ function as defined by the following laboratory criteria: 
WBC >_3500/mm3, platelet count >_100,000/mm3. 
Bilirubin <2.0 mg/dl or SGOT <3.0 X the upper limit of normal. 
Creatinine <_1.6 mg/dl or creatinine clearance >_60 cc/min. 
Prior hormonal therapy is allowed as: 
1. Neoadjuvant treatment prior to radiation therapy or radical prostatectomy, provided that the total duration of exposure does not exceed 10 months. 
2. One cycle of intermittent therapy up to a maximum exposure of 10 months. 
Patients must be at least 18 years of age. 
Patients must have signed an informed consent document stating that they understand the investigational nature of the proposed treatment
{"Condition": ["progressing disease in bone", "progressing disease in soft tissue", "disease in bone", "localized disease", "disease", "metastatic disease", "prostate adenocarcinoma", "disease in soft tissue"], "Device": [], "Drug": [], "Measurement": ["minimum no. of determinations", "WBC", "maximum exposure", "SGOT", "Creatinine", "creatinine clearance", "PSA", "platelet count", "organ function", "total duration of exposure", "Bilirubin", "Minimal % increase in range of values", "Karnofskcy performance status (KPS)", "level of serum testosterone", "Minimal Baseline PSA value", "Interval"], "Mood": ["is allowed"], "Multiplier": ["One cycle"], "Negation": [], "Observation": ["adequate organ function", "history of", "Biochemical progression", "progression of disease", "radiographic evidence"], "Person": ["age"], "Procedure": ["hormonal therapy", "Neoadjuvant treatment", "radiation", "radiographic", "radical prostatectomy", "intermittent therapy", "surgery", "treatment", "histologically", "radiation therapy"], "Qualifier": ["histologically confirmed", "Non-castrate", "definitive", "radiographically evident", "metastatic", "biochemically"], "ReferencePoint": ["radiation therapy or radical prostatectomy", "the time of diagnosis", "treatment for localized disease"], "Scope": ["disease or progressing disease in bone or in soft tissue", "Non-castrate metastatic", "at the time of diagnosis or after treatment for localized disease", "minimum no. of determinations: 3 Interval: \u003e2 weeks Minimal Baseline PSA value (ng/ml): 2 Minimal % increase in range of values: 50%", "radiation or surgery"], "Temporal": ["newly detected", "Prior", "after treatment for localized disease", "at the time of diagnosis", "prior to radiation therapy or radical prostatectomy"], "Value": ["at least 18 years", "above the lower limit of normal", "\u003e_70%", "\u003c2.0 mg/dl", "does not exceed 10 months", "\u003c_1.6 mg/dl", "\u003e2 weeks", "3", "Rising", "10 months", "\u003e_60 cc/min", "adequate", "\u003c3.0 X the upper limit of normal", "\u003e_3500/mm3", "50%", "\u003e_100,000/mm3", "confirmed", "(ng/ml): 2"], "Visit": []}